Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marqibo in Relapsed/Refractory AML
NCT02337478Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2015
- Primary completion
- Mar 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vincristine in acute myeloid leukemia (AML), sponsored by Wake Forest University Health Sciences. Started Jun 2015; status: terminated.
02
Drugs
vincristine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02337478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337478.